APLT - NASDAQ

Applied Therapeutics, Inc.

Applied Therapeutics, Inc.

APLT·NASDAQ

$0.91

+0.0000%
HealthcareBiotechnology

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$131.07M
EPS-0.7600
P/E Ratio-1.13
Earnings Date11/13/2025
86.69M
Assets
58%
3Y-4.0%
5Y+79.0%
10Y+2538.0%
29.68M
Total Liabilities
-59%
3Y+9.0%
5Y+88.0%
10Y+310.0%
57.01M
Total Equity
-432%
3Y-9.0%
5Y+75.0%
10Y-1539.0%
aplt

Applied Therapeutics, Inc. Funding & Solvency Profile

APLT · NASDAQ
Cash & Cash Equivalents79.40M
Net Receivables0.00
Inventory0.00
Other Current Assets461.00K
Total Current Assets84 M
Property, Plant & Equipment2.79M
Goodwill & Intangible Assets0.00
Long-Term Investments0.00
Other Non-Current Assets253.00K
Total Non-Current Assets3 M
Total Assets
86.69M

Financial Health Analysis

Current Ratio

3.06x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.52x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

56 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

96% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Applied Therapeutics, Inc. Balance Sheet

APLT • NASDAQ

Applied Therapeutics, Inc. Balance SheetDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents
79.4M
49.9M
16.7M
53.9M
57.5M
18.9M
18.7M
3.3M
Short-Term Investments
0.0
0.0
13.9M
26.9M
39.4M
20M
0.0
0.0
Cash & Short-Term Investments
79.4M
49.9M
30.6M
80.8M
96.8M
38.9M
18.7M
3.3M
Net Receivables
0.0
285K
275K
525K
505K
0.0
0.0
0.0
Other Receivables
0.0
285K
275K
525K
505K
0.0
0.0
0.0
Inventory
0.0
3.3M
0.0
-525K
-505K
0.0
0.0
0.0
Prepaids
3.8M
1.4M
4.6M
5M
3.5M
7.2M
1.1M
9K
Other Current Assets
461K
-434K
1.8M
2.6M
2.2M
91K
388K
0.0
Total Current Assets
83.6M
54.4M
37.3M
88.4M
102.6M
46.2M
20.2M
3.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)
2.8M
447K
1.1M
1.5M
1.9M
2.2M
0.0
0.0
Other Non-Current Assets
253K
0.0
0.0
0.0
0.0
0.0
300K
0.0
Total Non-Current Assets
3M
447K
1.1M
1.5M
1.9M
2.2M
300K
0.0
Other Assets
0.0
0.0
0.0
0.0
0.0
0.0
-300K
0.0
Total Assets
86.7M
54.8M
38.4M
89.9M
104.5M
48.4M
20.2M
3.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables
4.4M
1.7M
4.5M
9.5M
640K
8.8M
3M
713K
Accounts Payable
4.4M
1.7M
4.5M
9.5M
640K
8.8M
3M
713K
Accrued Expenses
15.3M
11.9M
2.3M
2.8M
18.6M
4.7M
1.3M
280K
Short Term Debt
0.0
310K
622K
789K
1.1M
356K
0.0
0.0
Capital Lease Obligations (Current)
406K
429K
477K
442K
406K
356K
0.0
0.0
Deferred Revenue
212K
667K
0.0
14.8M
0.0
4.7M
0.0
0.0
Other Current Liabilities
6.9M
56.2M
25.5M
-1.8M
553K
-4.8M
110K
0.0
Total Current Liabilities
27.3M
71.2M
33.4M
26.5M
21.2M
14.1M
4.4M
993K
NON-CURRENT LIABILITIES
Long Term Debt
0.0
0.0
464K
891K
0.0
1.7M
0.0
0.0
Other Non-Current Liabilities
0.0
759K
0.0
-891K
0.0
-1.7M
0.0
6.3M
Total Non-Current Liabilities
2.4M
797K
878K
891K
1.3M
1.7M
0.0
6.3M
Capital Lease Obligations
2.8M
467K
891K
1.3M
1.7M
2M
0.0
0.0
Total Liabilities
29.7M
72M
34.3M
27.4M
22.6M
15.8M
4.4M
7.2M
SHAREHOLDERS' EQUITY
Preferred Stock
0.0
0.0
0.0
0.0
0.0
48.4M
35.4M
6.3M
Common Stock
35K
8K
5K
3K
2K
1K
0.0
0.0
Additional Paid-In Capital
631.2M
451.4M
352.8M
329M
242.8M
99.4M
1.7M
775K
Retained Earnings
-574.2M
-468.6M
-348.8M
-266.3M
-160.7M
-66.8M
-21.3M
-4.7M
Accumulated Other Comprehensive Income/Loss
0.0
0.0
51K
-107K
-112K
-2K
0.0
0.0
Other Total Stockholders' Equity
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-6.3M
Total Stockholders' Equity
57M
-17.1M
4.1M
62.5M
81.9M
32.6M
15.8M
-4M
Total Equity
57M
-17.1M
4.1M
62.5M
81.9M
32.6M
15.8M
-4M
SUMMARY
Total Liabilities & Equity
86.7M
54.8M
38.4M
89.9M
104.5M
48.4M
20.2M
3.3M
Total Investments
0.0
0.0
13.9M
26.9M
39.4M
20M
0.0
0.0
Total Debt
2.8M
777K
2M
2.1M
2.8M
2M
0.0
0.0
Net Debt
-76.6M
-49.1M
-14.7M
-52.6M
-55.7M
-16.8M
-18.7M
-3.3M
Shares Outstanding
144,012,125
144,012,125
144,012,125
144,012,125
144,012,125
144,012,125
144,012,125
144,012,125

SEC Filings

APLT - Filing history and reports

No SEC filings available for APLT

Related Guides

Blog Categories

Continue your APLT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.